

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5

Applicant: Peter HUDSON et al.  
Title: BENZAMIDE DERIVATIVES AS OXYTOCIN  
AGONISTS AND VASOPRESSIN  
ANTAGONISTS  
Appl. No.: 10/541,460  
Filing Date: March 6, 2006  
Examiner: Unassigned  
Art Unit: Unassigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

The relevance of the foreign-language documents is described on page 17 of the specification. An English translation of the foreign-language documents is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date 6 March 2006

By S. A. Bent

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Date Submitted: March 6, 2006

(use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	10/541,460
Filing Date	March 6, 2006
First Named Inventor	Peter HUDSON
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	052209-0138

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B1	Thomas BOSSMAR et al., "Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions", British Journal of Obstetrics & Gynaecology, April 1997, Vol. 104, pp. 471-477.	
	B2	R. BROUARD et al., "Effect of SR49059 an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea", British Journal of Obstetrics & Gynaecology, May 2000, Vol. 107, pp. 614-619.	
	B3	Venkatesan ARANAPAKAM et al., '4,10-DIHYDRO-5H-THIENO[3,2-c][1]BENZAZEPINE DERIVATIVES AND 9,10-DIHYDRO-4H-THIENO[2,3-c][1]BENZAZEPINE DERIVATIVES AS ORALLY ACTIVE ARGININE VASOPRESSIN RECEPTOR AGONISTS", Bioorganic & Medicinal Chemistry Letters 9 (1999) pp. 1733-1736.	
	B4	M. ARTICO et al., "RICERCHE SU SOSTANZE AD ATTIVITA ANTIBLASTICA", Il Farmaco, Ed. Sc. Vol. 24, no. 3, pp. 276-284.	
	B5	F. CHIMENTI et al., "RICERCHE SU SOSTANZE AD ATTIVITA ANTIBLASTICA", Il Farmaco, Ed. Sc. Vol. 32, no. 5, pp. 339-347.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/541,460
Date Submitted: March 6, 2006			Filing Date	March 6, 2006
<i>(use as many sheets as necessary)</i>			First Named Inventor	Peter HUDSON
			Group Art Unit	Unassigned
			Examiner Name	Unassigned
Sheet	2	of 2	Attorney Docket Number	052209-0138

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	B6	Jiban K. CHAKRABARTI et al., "4-piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics", J. Med. Chem. 1980, 23, pp. 878-884.		
	B7	Jiban K. CHARABARTI et al., "10-Piperazinyl-4H-thieno[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as Potential Neuroleptics", J. Med. Chem. 1980, 23, pp. 884-889.		
	B8	Jiban K. CHARABARTI et al., 'Synthesis and Pharmacological Evaluation of a Series of 4-Piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as Potential Anxiolytics", J. Med. Chem. 1989, 32, pp. 2573-2582.		
	B9	Alba CHIMIRRI et al., "ANNELATED 1,5-BENZODIAZEPINES. PART I. THREE, FOUR, AND FIVE MEMBERED RINGS", HETEROCYCLES, VOL. 36, NO. 3, 1993, PP. 601-637.		
	B10	Gary L. GUNEWALD et al., "Effect of Ring Size or an Additional Heteroatom on the Potency and Selectivity of Bicyclic Benzylamine-Type Inhibitors of Phenylethanolamine N-Methyltransferase", J. MED. CHEM. 1996, 39, 3539-3546.		
	B11	Janice M. KLUNDER et al., "Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2. Tricyclic Pyridobenzoxazepinones and Dibenzoxazepinones", J. Med. Chem., 1992, 35, pp. 1887-1897.		
	B12	Jean-Françoise F. LIÉGEOIS et al., "Pyridobenzoxazepine and Pyridobenzothiazepine Derivates as Potential Central Nervous System Agents: Synthesis and Neurochemical Study", J. Med. Chem. 1994, 37, pp. 519-525.		
	B13	Timothy O. OLAGBEMIRO et al., "Alkylation and an Unusual Reductive Ring Opening of Some Thieno[3,4-b][1,5]benzoxazepin-10-ones", Department of Chemistry, Bayero University, Kano, Nigeria, VOL 19, NOV-DEC 1982, pp. 1501-1504		
	B14	William B. WRIGHT Jr. et al., "Derivatives of 11-(1-Piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine as Central Nervous Systems Agents", J. Med. Chem. 1980, 23, pp. 462-465.		
	B15	Satoru SASATANI et al., "DIISOBUTYLALUMINUM HYDRIDE A NOVEL REAGENT FOR THE REDUCTION OF OXIMES", Tetrahedron Letters, Vol. 24, No. 43, pp. 4711-4712, 1983.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.